Vigil Neuroscience (VIGL) reported positive data from completed Phase 1 clinical
trial evaluating VG-3927 for the potential treatment of Alzheimers disease. The company said, collectively, the safety, tolerability, pharmacokinetic, and pharmacodynamic profile supports the advancement of VG-3927 into a Phase 2 clinical trial as a
potential once-daily oral therapy for AD.
Based on the Phase 1 results and preclinical profile of VG-3927, the company plans to advance a once-daily oral dose of 25mg that fully engages the desired pharmacology and expects to begin the Phase 2 trial in the third quarter of 2025.
For More Such Health News, visit rttnews.com.
For comments and feedback: editorial@rttnews.com